In the published article, there were errors in Figure 3 as published. In part A, the binding site is the “zilucoplan binding site”, rather than the “eculizumab binding site”. In part D, “nonspecific proteinases” should be “nonspecific proteases”. The corrected Figure 3 and its caption appear below.
Figure 3
In the published article, there was an error. The Introduction incorrectly states that zilucoplan is composed of a 15-amino acid macrocyclic peptide including three unnatural amino acids. Zilucoplan is composed of a 15-amino acid macrocyclic peptide including four unnatural amino acids.
A correction has been made to Introduction, paragraph 4. This sentence previously stated:
“It is composed of a 15-amino acid macrocyclic peptide, including three unnatural amino acids, designed to inhibit TCC activation”
The corrected sentence appears below:
“It is composed of a 15-amino acid macrocyclic peptide, including four unnatural amino acids, designed to inhibit TCC activation”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
complement activation, C5 cleavage, C5 R885 variants, C5b6, MAC formation, macrocyclic peptide inhibitor, RBC hemolysis, permeability
Citation
Tang G-Q, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang J-G, Bu C, Cong B, Palmer E, Duda PW, Sayegh C and Ricardo A (2023) Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front. Immunol. 14:1282155. doi: 10.3389/fimmu.2023.1282155
Received
23 August 2023
Accepted
08 September 2023
Published
25 September 2023
Volume
14 - 2023
Edited and reviewed by
Marie-Agnes Dragon-Durey, Université Paris Cité, France
Updates
Copyright
© 2023 Tang, Tang, Dhamnaskar, Hoarty, Vyasamneni, Vadysirisack, Ma, Zhu, Wang, Bu, Cong, Palmer, Duda, Sayegh and Ricardo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guo-Qing Tang, GuoQing.Tang@ucb.com
†Present addresses: Ketki Dhamnaskar, Nurix Therapeutics, San Francisco, CA, United States; Michelle D. Hoarty, Dyne Therapeutics, Waltham, MA, United States; Douangsone D. Vadysirisack, Dianthus Therapeutics, Waltham, MA, United States; Zhong Ma, Mariana Oncology, Watertown, MA, United States; Rohit Vyasamneni, BioNTech SE, Cambridge, MA, United States; Nanqun Zhu, Avilar Therapeutics, Waltham, MA, United States; Camil Sayegh, Mitochondria Emotion Inc., Cambridge, MA, United States; Alonso Ricardo, Mariana Oncology, Watertown, MA, United States
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.